Regeneron Pharmaceuticals (REGN) Total Current Liabilities (2009 - 2026)

Regeneron Pharmaceuticals' Total Current Liabilities history runs 18 years deep, the most recent figure standing at $5.5 billion for Q2 2026.

• In Q2 2026, Total Current Liabilities rose 50.82% year-over-year to $5.5 billion; the TTM figure through Jun 2026 stood at $5.5 billion (up 50.82% YoY), while the FY2025 annual figure was $4.4 billion, up 10.75% from the prior year.
• Total Current Liabilities for Q2 2026 stood at $5.5 billion, up from $5.1 billion in the prior quarter.
• The five-year high for Total Current Liabilities was $5.5 billion in Q2 2026, with the low at $2.9 billion in Q3 2022.
• The 5-year median for Total Current Liabilities is $3.6 billion (2024), against an average of $3.7 billion.
• The sharpest annual moves came in 2022 and 2026: Total Current Liabilities decreased 22.49% in 2022, then surged 50.82% in 2026.
• Regeneron Pharmaceuticals' Total Current Liabilities stood at $3.1 billion in 2022, then climbed by 8.98% to $3.4 billion in 2023, then gained by 15.22% to $3.9 billion in 2024, then grew by 10.75% to $4.4 billion in 2025, then increased by 26.6% to $5.5 billion in 2026.
• Business Quant data shows REGN's Total Current Liabilities at $5.5 billion in Q2 2026, $5.1 billion in Q1 2026, and $4.4 billion in Q4 2025.